Stability Studies for Biologics

  • Anthony Mazzeo
  • Patrick Carpenter


Biological products represent a growing segment of the pharmaceutical industry. Stability studies of these complex biologics present challenges beyond those found for the typical small-molecule pharmaceutical. Biologic products are typically only marginally stable, not entirely understood, may demonstrate non-Arrhenius behavior, degrade by multiple pathways and possibly different pathways during different stages of shelf life. Further, subtle changes brought on by stresses can have large effects on the therapeutic properties of the product. There are analytical methodology challenges pertaining to monitoring stability as well, in particular the higher variance and complexity of the product and methodology. The issues and strategies involved in studying the stability of biologic protein products, particularly for the purposes of product registration purposes are discussed as well as an overview of ICH Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products. Stability protocols should be designed keeping in mind the idiosyncrasies of biologics as well as formulation, analytical, manufacturing, and regulatory knowledge gained during development.


Shelf Life Stability Study Drug Substance Subvisible Particle Biologics License Application 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mikkelsen SR, Cortòn E (2004) Bioanalytical Chemistry. Wiley Interscience, Hoboken.CrossRefGoogle Scholar
  2. 2.
    Jacob S, Shirwaikar AA, Srinivasan KK, Alex J, Prabu SL, Mahalaxmi R, Kumar R (2006) Stability of proteins in aqueous solution and solid state. Indian J Pharm Sci 68(2):154–163.CrossRefGoogle Scholar
  3. 3.
    Chan H, Dill K (1998) Protein folding in the landscape perspective: chevron plots and non-arrhenius kinetics. Proteins: Struct Funct Genet 30:2–33.CrossRefGoogle Scholar
  4. 4.
    Collet O, Chipot C (2003) Non-arrhenius behavior the unfolding of a short hydrophobic upalpha-helix. complementarity of molecular dynamics and lattice model simulations. J Am Chem Soc 125:6573–6580.CrossRefPubMedGoogle Scholar
  5. 5.
    Roberts CJ, Darrington RT, Whitley MB (2003) Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. J Pharm Sci 92(5):1095–1111.CrossRefPubMedGoogle Scholar
  6. 6.
    Pan B, Abel J, Ricci MS, Brems DN, Wang DIC, Trout BL (2006) Comparative oxidation studies of methionine residues reflect a structural effect of chemical kinetics in rhG-CSF. Biochemistry 45:15430–15443.CrossRefPubMedGoogle Scholar
  7. 7.
    Yoshioka S, Aso Y, Izutsu K, Terao T (1994) Application of accelerated testing to shelf-life prediction of commercial protein preparations. J Pharm Sci 83(3):454–456.CrossRefPubMedGoogle Scholar
  8. 8.
    Kerwin BA, Remmele RL (2007) Protect from light: photostability and protein biologics. J Pharm Sci 96(6):1468–1479.CrossRefPubMedGoogle Scholar
  9. 9.
    Mizutani, T (1981) Estimation of protein and drug adsorption onto silicone-coated glass surfaces. J Pharm Sci 70(5):493–496.CrossRefPubMedGoogle Scholar
  10. 10.
    Cohen S, Price C, Vlasak J (2007) β-Elimination and peptide bond hydrolysis: two distinct mechanisms of human IgG1 hinge fragmentation upon storage. JACS 129:6976–6977.CrossRefGoogle Scholar
  11. 11.
    Cordoba AJ, Shyong B, Breen D, Harris RJ (2005) Non-enzymatic hinge region fragmentation of antibodies in solution. J Chrom B 818:115–121.CrossRefGoogle Scholar
  12. 12.
    Werner R, Kopp K, Schlueter, M (2007) Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 96(455):17–22.PubMedGoogle Scholar
  13. 13.
    Werne SJ, Creighton TE (1989) Effect of protein conformation on rate of deamidation: ribonuclease a. Proteins: Struct Funct Genet 5:8–12.CrossRefGoogle Scholar
  14. 14.
    Tsai AM, Van Zanten JH, Betenbaugh MJ (1998) Study of protein aggregation due to heat denaturation: a structural approach using circular dichroism spectroscopy, nuclear magnetic resonance and static light scattering. Biotechnol Bioeng 59:273–280.CrossRefPubMedGoogle Scholar
  15. 15.
    Kendrick BS, Cleland JL, Lam X, Nguyen T, Randolph TW, Manning MC, Carpenter JF (1998) Aggregation of recombinant human interferon gamma: kinetics and structural transitions. J Pharm Sci 87(9):1069–1076.CrossRefPubMedGoogle Scholar
  16. 16.
    Chi EY,Krishnam S, Randolph TW, Carpenter JF (2003) Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 20(9):1325–1336.CrossRefPubMedGoogle Scholar
  17. 17.
    Li S, Shöneich C, Borchardt, RT (1995) Chemical instability of protein pharmaceuticals: mechanisms of oxidation and strategies for stabilization. Biotechnol Bioeng 48:490–500.CrossRefPubMedGoogle Scholar
  18. 18.
    Xie M, Schowen R, (1999) Secondary structure and protein deamidation. J Pharm Sci 88(1):8–13.CrossRefPubMedGoogle Scholar
  19. 19.
    Luo D, Smith SW, Anderson BD (2005) Kinetics and mechanism of the reaction of cysteine and hydrogen peroxide in aqueous solution. J Pham Sci 94(2):304–316.CrossRefGoogle Scholar
  20. 20.
    Cleland JL, Lam X, Kendrick B, Yang J, Yang T, Overcashier D, Brooks D, Hsu C, Carpenter J (2001) A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. J Pharm Sci 90(3):310–321.CrossRefPubMedGoogle Scholar
  21. 21.
    Constantino HR, Carrasquillo, KG, Cordero RA, Mumenthaler M, Hsu CC, Gribenow K (1998) Effect of excipients on the stability and structure of lyophilized recombinant human growth hormone. J Pharm Sci 87(11):1412–1420.CrossRefGoogle Scholar
  22. 22.
    Lai MC, Topp EM (1999) Solid-state chemical stability of proteins and peptides. J Pharm Sci 88(5):489–500.CrossRefPubMedGoogle Scholar
  23. 23.
    Li S, Patapoff TW, Overcashier, D, Hsu C, Nguyen TH, Borchardt RT (1996) Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state. J Pharm Sci 85(8):873–877.CrossRefPubMedGoogle Scholar
  24. 24.
    Kreilgaard L, Jones LS, Randolph TW, Frokjaer, Flink JM, Manning MC, Carpenter JF (1998) Effect of tween 20 on freeze–thawing- and agitation-induced aggregation of recombinant human factor XIII. J Pharm Sci 87(12):1597–1603.PubMedGoogle Scholar
  25. 25.
    Jones LS, Kaufmann A, Middaugh CR (2005) Silicon oil induced aggregation of proteins. J Pharm Sci 94(4):918–927.CrossRefPubMedGoogle Scholar
  26. 26.
    PDA (Parenteral Drug Association) (2007) Technical report no. 39, Guidance for temperature-controlled medicinal products: maintaining the quality of temperature-sensitive medicinal products through the transportation environment.Google Scholar
  27. 27.
    The Gold Sheet, (September 2006) Global effort to control drug temperature in transit heats up. 40(9):1–19.Google Scholar
  28. 28.
    Martin SWH, Mo J (2007) Stability considerations for lyophilized biologics. Am Pharm Rev 10(4):31–36.Google Scholar
  29. 29.
    Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJA, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S, Clouse KA, Swann PG, Rosenberge A, Cherney B (2008) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J pharm sci (early view):1–5.Google Scholar
  30. 30.
    Fairweather WR, Mogg R, Bennett PS, Zhong J, Morrisey C, Schofield TL (2003) Monitoring the stability of human vaccines. J Biopharm Stat 13(3):395–413.CrossRefPubMedGoogle Scholar
  31. 31.
    Schofield T, Apostol I, Koehler G, Powers S, Stawicki M, Wolfe R (2008) A rational approach to setting and maintaining specifications for biological and biotechnology-derived products. Biopharm International, (July 2008): 1–4.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Exploratory Biopharmaceutics and Stability, Pharmaceutical Development DepartmentBristol-Myers Squibb CompanyNew BrunswickUSA
  2. 2.University of KansasUSA

Personalised recommendations